GT20029, the twice-weekly topical PROTAC for hair loss: what Phase 2 means for Malaysians waiting on new drugs

In April 2024 a Chinese biotechnology company, Kintor Pharmaceutical, announced that its experimental scalp drug GT20029 had met the main goal of a phase 2 trial in Chinese men with pattern hair loss. In December 2025 the full study was published in the Journal of Dermatological Treatment. The same company also makes pyrilutamide (KX-826), a different topical anti-androgen that is further along in development, so the two drugs are easy to mix up. GT20029 is not another receptor blocker. It is designed as a proteolysis-targeting chimera, or PROTAC: a molecule that tags the androgen receptor for destruction inside the cell.

This guide explains how that idea is meant to work, what the phase 2 numbers actually showed, how GT20029 compares with treatments that exist today, what is still unknown, and what a sensible plan looks like for a Malaysian reader while the drug remains unapproved. It is general information, not personal medical advice. For related reading, see pyrilutamide (KX-826), clascoterone, and how DHT drives hair loss.

The short answer

• GT20029 is an experimental topical androgen-receptor degrader. It is a liquid applied to the scalp, developed by Kintor as a PROTAC that recruits the cell's own protein-disposal machinery to break down androgen receptors in skin tissue ^{1 2}.
• Phase 2 in China met its primary endpoint. In 180 men treated for 12 weeks, the 0.5% once-daily arm gained 16.80 hairs/cm² versus 10.10 on matched placebo, and the 1.0% twice-weekly arm gained 11.94 versus 4.57 ^{2 3}.
• Twice-weekly 1.0% was chosen for later trials. The company selected that regimen as the recommended dose for phase 3, partly because a dose-response pattern appeared in the twice-weekly arms and hair width also improved versus placebo ^{1 4}.
• It is not approved anywhere yet. As of the company's August 2026 interim report, a China phase IIb/III trial for male pattern hair loss was planned for the second half of 2026, and a U.S. phase 2 was also planned ⁵.
• It is not available in Malaysia. There is no NPRA-registered GT20029 product to buy as a medicine here ⁶.
• Proven options exist today. Topical minoxidil and, for men, oral finasteride or dutasteride remain the best-studied medical treatments for pattern hair loss while new drugs move through trials ^{7 8}.

What GT20029 is

GT20029 is a small-molecule drug candidate from Kintor Pharmaceutical (Hong Kong stock code 9939). The company describes it as the first topical PROTAC compound to complete phase 1 trials in both China and the United States, and later as the first topical PROTAC to finish a phase 2 programme for androgenetic alopecia ^{1 5}.

In the China phase 2 hair-loss trial the product was a tincture (an alcohol-based topical solution) sprayed onto the thinning area of the scalp. Arms used either 0.5% or 1.0% strength, either once daily or twice weekly ^{9 2}.

Kintor is also developing GT20029 for acne, because androgen signalling in the pilosebaceous unit is involved in both conditions. An acne phase 2 readout was positive in 2025, with 0.5% selected as the recommended phase 3 dose for that indication ⁵. This article focuses on the hair-loss programme.

How pattern hair loss works, and where a PROTAC fits

The hair cycle

Each scalp follicle cycles through a long growing phase (anagen), a short transition (catagen) and a resting phase (telogen), after which the old hair sheds and a new one starts ¹⁰. On a healthy scalp anagen lasts years, which is why scalp hair can grow long.

Miniaturisation and DHT

In androgenetic alopecia, follicles in genetically sensitive areas respond to androgens. An enzyme called 5-alpha reductase converts testosterone into dihydrotestosterone (DHT). DHT binds androgen receptors inside follicle cells. Over many cycles the growing phase shortens and the follicle shrinks, so thick pigmented hairs are gradually replaced by thin, short, pale ones ^{11 12}. In men this typically shows as a receding hairline and thinning crown. See male pattern baldness treatment for the clinical picture.

Three ways to interrupt the pathway

1. Lower DHT production. Finasteride and dutasteride inhibit 5-alpha reductase so less DHT is made ¹¹. See finasteride and dutasteride.
2. Block the receptor. Androgen-receptor antagonists such as pyrilutamide and clascoterone occupy the receptor so DHT cannot switch it on ^{13 14}.
3. Remove the receptor. A PROTAC is built as a bifunctional molecule: one end binds the target protein (here the androgen receptor), the other recruits an E3 ubiquitin ligase. The ligase marks the receptor with ubiquitin tags, and the proteasome then degrades it. In principle the drug can catalyse the destruction of many receptor molecules rather than simply occupying them one-to-one ^{1 2}.

Minoxidil sits outside this hormone pathway. It is thought to prolong anagen and enlarge follicles through effects on blood flow and follicle cells ¹¹. That is why doctors often combine a hormone-pathway drug with minoxidil. See minoxidil in Malaysia and using minoxidil and finasteride together.

Why a topical degrader is interesting on paper

Oral anti-androgens act throughout the body. Finasteride helps many men, but a minority report sexual side effects, and that worry stops some from starting ¹⁵. A drug that acts mainly in skin, with low blood levels, could in theory spare some of those concerns. Phase 1 work on GT20029 reported very low systemic exposure after topical use, and the company emphasises local action in the pilosebaceous unit ^{5 4}. That design goal is plausible. It is not the same as long-term proof in large populations.

What the phase 2 trial actually showed

Design

The published phase 2 study was a multicentre, randomised, double-blind, placebo-controlled trial at 12 sites in China. From April 2023 to April 2024, 180 eligible adult men with Hamilton-Norwood stages IIIv to V were assigned equally to six groups: GT20029 0.5% or 1.0%, or matching placebo, each given either once daily (QD) or twice weekly (BIW) for 12 weeks, then followed for 28 days off treatment ^{2 9}. The registry identifier is NCT06692465. The leading principal investigator was Professor Yang Qinping of Fudan University Huashan Hospital ¹.

Participants applied about seven sprays (roughly 1 ml) to the affected scalp area on dosing days ². The primary endpoint was change from baseline in target-area non-vellus hair count (TAHC) at week 12. Secondary measures included TAHC at week 6, target-area hair width (TAHW), and the terminal-to-vellus ratio ⁹.

Efficacy numbers

All four active groups improved TAHC from baseline at week 12. Compared with matched placebo, two arms reached statistical significance on the primary between-group contrast ^{2 4}:

The company also reported that the 0.5% once-daily arm was about 6.69 hairs/cm² above its placebo, and the 1.0% twice-weekly arm about 7.36 hairs/cm² above its placebo ³. A dose-response trend was clearer in the twice-weekly cohorts than in the daily cohorts ².

Hair width also mattered. The 1.0% twice-weekly group improved TAHW versus placebo at week 12 (0.54 vs −0.02 mm/cm², p=0.011) ^{2 4}. That is one reason the company called 1.0% twice weekly the optimal dose for phase 3 ¹.

Subgroup signals in secondary analyses suggested larger responses in some men with moderate baseline severity, higher baseline hair counts, age 40 or under, or no prior AGA treatment, especially on the twice-weekly 1.0% arm. Those are exploratory patterns, not proven patient-selection rules ⁴.

Safety

Among 179 people in the safety set, about 50.8% had at least one treatment-emergent adverse event, with similar rates on active drug and placebo. Drug-related events occurred in about 12.3% overall (14.4% active, 8.2% placebo). The most common drug-related local issues were application-site itch (about 7.3%) and dermatitis (about 1.1%). Grade 3 or higher events were uncommon (about 2.2%) and were judged unrelated to study drug; no GT20029-treated participant discontinued for an adverse event in the published summary ^{2 4}. The company also stated that no adverse sexual events were observed in the trial ³. Pharmacokinetic sampling in a subset showed low and variable systemic exposure without a clear dose-exposure relationship ⁴.

How to read a 12-week phase 2

A positive phase 2 is encouraging. It is not a licence to treat patients. Limits to keep in mind:

• The study enrolled 180 men, about 30 per arm, for only 12 weeks. Pattern hair loss is a decades-long process ¹².
• All efficacy data so far are from Chinese men. Results in women, other ethnic groups, or people already on minoxidil or finasteride are not established by this trial ⁹.
• Placebo arms also gained hairs, which is common in hair trials when participants care for their scalp more carefully. The drug must beat that effect.
• There is no head-to-head comparison yet with finasteride, dutasteride, minoxidil, pyrilutamide or clascoterone.
• Peer-reviewed publication strengthens the record, but phase 3 confirmation is still required ^{2 5}.

Comparison with options people actually use

Numbers from different trials cannot be stacked as a league table. Populations, photography methods, treatment length and placebo responses all differ.

Pros, cons and risks

Possible advantages

• Novel mechanism: receptor degradation rather than simple blockade ¹.
• Twice-weekly dosing in the preferred arm may be easier to stick with than twice-daily liquids, if phase 3 confirms benefit ¹.
• Local application with low measured blood levels in early studies ^{4 5}.
• No sexual adverse events reported in the 12-week China phase 2 ³.
• Trial population was Asian men, which is relevant for many Malaysian readers ².

Limits and unknowns

• Not approved by any major regulator, including Malaysia's NPRA ^{6 5}.
• Only 12 weeks of controlled efficacy data in 180 men ².
• Not studied here in women, or as add-on to minoxidil or oral anti-androgens.
• Local itch and dermatitis can occur ⁴.
• Alcohol-based scalp liquids can sting or dry the skin, especially in hot, humid weather.
• Like other pattern-hair-loss treatments, any benefit would be expected to fade if treatment stops, because follicle sensitivity remains ¹².
• The sponsor's other AR drug, pyrilutamide, had a failed phase 3 at a lower dose before a later success, which is a reminder that mid-stage wins are not the same as late-stage wins ^{16 17}.

Timelines: what is planned, not promised

Nobody can fix a launch date in advance. Based on company disclosures:

1. China phase IIb/III. Kintor stated in its August 2026 interim results that it planned to start a phase IIb/III trial of GT20029 for male AGA in China in the second half of 2026 ⁵.
2. U.S. phase 2. The same disclosure mentioned plans for a U.S. male AGA phase 2 ⁵.
3. Approval and Malaysia. Even after successful late-stage trials, each country has its own review. China approval would not automatically mean Malaysian registration. Check NPRA's product search before believing any online listing ⁶.
4. If it ever reaches patients. Hair-count gains in trials are usually judged over months. Everyday users of existing drugs often need three to six months to judge shedding and a year for a fair density check ⁸.

Malaysian context

Availability. GT20029 is an investigational medicine. It is not a registered treatment you can buy in a Malaysian pharmacy today ⁶.

Online "PROTAC" or "GT" products. Treat unverified scalp liquids sold on marketplaces with caution. Counterfeit or mislabelled products are a real risk. Registration status can be checked on the NPRA portal ⁶.

Climate and adherence. Malaysia is hot and humid. Sweat, helmets, frequent washing and prayer-related wetting of the hair can all affect how long a topical stays on the scalp. Twice-weekly dosing sounds convenient, but only if the liquid can dry and stay in contact as the protocol intends. Those practical points matter for any topical, including minoxidil.

Diagnosis first. Not every thinning pattern is androgenetic alopecia. Telogen effluvium after illness, thyroid disease, iron deficiency and scalp disorders need different care. A registered doctor can help confirm the diagnosis; registration can be checked via the Malaysian Medical Council ¹⁸. See chronic telogen effluvium if shedding feels sudden and diffuse.

Cost. Because the drug is not sold here as a medicine, this article lists no local price.

Myths

"A PROTAC is just stronger finasteride." Finasteride lowers DHT production. GT20029 is designed to degrade androgen receptors in skin. Different step in the pathway ^{2 11}.

"Phase 2 success means it will be in pharmacies next year." Phase 3, manufacturing and national reviews still sit ahead ⁵.

"Twice weekly means it is already better than daily minoxidil." There is no head-to-head trial. Convenience is not the same as proven superiority.

"No sexual side effects in a 12-week study means lifelong safety." Short trials cannot settle long-term risk. Larger and longer studies are needed ².

"Waiting for GT20029 is safer than starting treatment now." Pattern hair loss tends to progress. Follicles that have been miniaturising for years respond less well later ¹². Proven options exist now ⁷.

"Anything labelled anti-androgen gel online is the trial drug." The trial product is a specific investigational tincture under clinical protocols, not a generic marketplace gel ⁹.

Practical checklist

• Confirm the diagnosis with a doctor before changing any routine.
• Take baseline photos every three months in the same light.
• If you are a man with early-to-moderate pattern loss, ask about evidence-based options available today, such as topical minoxidil and, where suitable, finasteride or dutasteride ⁷.
• If oral anti-androgens worry you, discuss real evidence on side effects rather than forum anecdotes ¹⁵. See post-finasteride syndrome.
• Do not buy unverified "GT20029" liquids online. Check NPRA registration for any product sold with medical claims ⁶.
• Follow GT20029 through primary sources: ClinicalTrials.gov, peer-reviewed journals and company exchange filings, not only social media summaries.
• Reassess when phase IIb/III results are public, not on the basis of a single phase 2 headline.

Bottom line

GT20029 is one of the more distinctive experimental hair-loss drugs in late mid-stage testing because it tries to destroy androgen receptors in the scalp rather than only block them, and because a twice-weekly dose has been nominated for late-stage trials after a positive China phase 2. The published gains over placebo are real but modest, the study was short, and the product is not approved in Malaysia. The practical move for most readers remains the same: get a clear diagnosis, use treatments that already have strong evidence where they suit you, and treat GT20029 as news to watch rather than a reason to delay care.

Frequently asked questions

What is GT20029?

It is an experimental topical androgen-receptor PROTAC (protein degrader) developed by Kintor Pharmaceutical for male pattern hair loss and also studied for acne.

Is GT20029 available in Malaysia?

No. It is not approved as a medicine anywhere yet, and it is not an NPRA-registered hair-loss drug you can buy in Malaysian pharmacies.

What did the phase 2 trial show?

In 180 Chinese men treated for 12 weeks, 0.5% once daily raised target-area hair count by 16.80 hairs/cm² versus 10.10 on placebo, and 1.0% twice weekly raised it by 11.94 versus 4.57. Local side effects were mostly mild itch or dermatitis.

How is GT20029 different from pyrilutamide or finasteride?

Finasteride lowers DHT production. Pyrilutamide and clascoterone block the androgen receptor. GT20029 is designed to tag the receptor for destruction inside the cell.

Why does twice-weekly dosing matter?

The company selected 1.0% twice weekly as the preferred phase 3 dose after phase 2 showed a clear benefit versus placebo on hair count and hair width. Whether that convenience holds up depends on phase 3.

When could it reach patients?

Kintor planned a China phase IIb/III start in the second half of 2026. Approval timelines after that are uncertain, and Malaysia would need its own registration decision.

Should someone wait for GT20029 instead of starting minoxidil or finasteride?

Usually no. Pattern hair loss tends to progress, and those older options already have far more evidence. Ask a doctor what suits you now.

Are online GT20029 gels the real drug?

Almost certainly not. The trial used a specific investigational tincture under protocol. Unverified marketplace liquids should be treated with caution.

Educational content. Not medical advice.